Dow Jones Newswires
May 30, 2003
KENILWORTH, N.J. -- Schering-Plough Corp. (SGP) said it has been advised by the U.S. Attorney's Office for the District of Massachusetts that its Schering Corp. unit is the target of a criminal investigation, and it believes the government intends to pursue an indictment.
The company, which previously announced that the government was investigating its sales, marketing and clinical-trial practices, said Friday that a May 28 letter from the U.S. Attorney's Office states the investigation focuses on whether it:
The drug maker has been struggling with the expiration of the patent for Claritin, its one-time blockbuster allergy drug. Earlier this month, Schering reported a 71% drop in first-quarter profit on falling sales of key drugs.
Last month, Fred Hassan took over as chief executive and president, and said his priority in the short term would be to repair relations with drug regulators, in part by tending to manufacturing problems.
-By Judy Bocklage; Dow Jones Newswires; 609-520-7811
Updated May 30, 2003 11:21 a.m.
|Return to: CPTech Home -> Main IP Page -> IP and Healthcare -> CPTech Page on Schering-Plough|